Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor-Driven Immunosuppression

The latest update is out from Cantargia AB ( (SE:CANTA) ).

Cantargia AB has published preclinical data in Cancer Discovery, highlighting the potential of nadunolimab to counteract tumor-driven systemic immunosuppression by targeting IL1RAP. The study, conducted by Professor Douglas Hanahan’s research group, demonstrates that blocking IL1RAP can overcome resistance to immune therapy in a cervical cancer model. The findings are supported by clinical data showing nadunolimab’s ability to reduce immunosuppressive cells, suggesting significant potential in improving cancer treatment outcomes.

More about Cantargia AB

Cantargia AB is a biotechnology company focused on developing antibody-based treatments for life-threatening diseases. The company has established a platform centered around the protein IL1RAP, which is involved in various cancer forms and inflammatory diseases. Cantargia’s primary oncology program features the antibody nadunolimab (CAN04), which is being studied in combination with chemotherapy for pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. The company is also developing CAN10 for autoimmune and inflammatory diseases.

YTD Price Performance: -2.61%

Average Trading Volume: 2,500

Technical Sentiment Signal: Buy

Current Market Cap: €36.77M

For detailed information about CANTA stock, go to TipRanks’ Stock Analysis page.